ALX Oncology, a biotechnology company listed on Nasdaq as ALXO, based in South San Francisco, revealed on June 30, 2026, that the Compensation Committee of its Board of Directors sanctioned an inducement stock option for Michael Listgarten, the new General Counsel. The option allows him to procure 500,000 shares of ALX Oncology’s common stock following his recruitment on June 29, 2026. The grant adheres to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and associated agreements. This offer was a crucial enticement for Listgarten to join ALX Oncology and complies with Nasdaq Listing Rule 5635(c)(4).